 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...1011121314151617181920...2425» |
- Leukine (sargramostim) / Partner Therap
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia (clinicaltrials.gov) - Mar 30, 2017
P2, N=0, Withdrawn, Sponsor: Sanofi
N=165 --> 0 | Initiation date: Jul 2017 --> Feb 2017 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2022 --> Feb 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Mar 29, 2017
P1, N=7, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
N=165 --> 0 | Initiation date: Jul 2017 --> Feb 2017 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2022 --> Feb 2017 Trial primary completion date: Aug 2014 --> Apr 2015
- | Clinical: NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders (clinicaltrials.gov) - Mar 29, 2017
P2, N=41, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Aug 2014 --> Apr 2015 Trial primary completion date: Jan 2017 --> May 2017
- | Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial primary completion date: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Mar 28, 2017
P2, N=29, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jan 2017 --> May 2017 Trial primary completion date: Dec 2017 --> Dec 2018
- | Leukine (sargramostim) / Partner Therap
Enrollment open: Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) - Mar 25, 2017
P2, N=15, Recruiting, Sponsor: University of Florida
Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Combination therapy: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma (clinicaltrials.gov) - Mar 14, 2017
P2, N=44, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Suspended
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion, Surgery: Surgery in Treating Children With Neuroblastoma (clinicaltrials.gov) - Mar 13, 2017
P3, N=968, Completed, Sponsor: Children's Oncology Group
Recruiting --> Suspended Active, not recruiting --> Completed
- ||| biropepimut-S (GL-0817) / Gliknik
Trial initiation date: Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) - Mar 13, 2017
P2, N=80, Not yet recruiting, Sponsor: Gliknik Inc.
Active, not recruiting --> Completed Initiation date: Nov 2016 --> Mar 2017
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date: Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Mar 9, 2017
P1, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Nov 2016 --> Mar 2017 Trial primary completion date: Sep 2017 --> Sep 2018
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed, Trial initiation date: Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (clinicaltrials.gov) - Mar 9, 2017
P2, N=25, Active, not recruiting, Sponsor: Fundaci
Trial primary completion date: Sep 2017 --> Sep 2018 Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Nov 2015
- | Leukine (sargramostim) / Partner Therap
Enrollment change, Trial termination: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (clinicaltrials.gov) - Feb 28, 2017
P2, N=2, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Nov 2015 N=10 --> 2 | Active, not recruiting --> Terminated; Slow Accrual
- | SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion, Trial primary completion date: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Feb 27, 2017
P1, N=9, Completed, Sponsor: Roswell Park Cancer Institute
N=10 --> 2 | Active, not recruiting --> Terminated; Slow Accrual Trial primary completion date: May 2017 --> May 2014 | Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial primary completion date: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy (clinicaltrials.gov) - Feb 27, 2017
P1, N=18, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: May 2017 --> May 2014 | Active, not recruiting --> Completed Trial primary completion date: Nov 2017 --> Nov 2018
- | Leukine (sargramostim) / Partner Therap
New P2 trial: Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) - Feb 24, 2017
P2, N=15, Not yet recruiting, Sponsor: University of Florida
- ||||||| NeuVax (nelipepimut-S) / Dr. Reddy's
Trial completion, Trial primary completion date: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - Feb 24, 2017
P3, N=700, Completed, Sponsor: Galena Biopharma, Inc.
Trial primary completion date: Nov 2017 --> Nov 2018 Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Sep 2016
- | Decadron (dexamethasone) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Trial primary completion date: Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 23, 2017
P2/3, N=60, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Sep 2016 Trial primary completion date: Jan 2017 --> Dec 2019
- |||| Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date, Combination therapy: Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 17, 2017
P2, N=119, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2017 --> Dec 2019 Active, not recruiting --> Completed | Trial primary completion date: Aug 2018 --> Jan 2017
- Leukine (sargramostim) / Partner Therap
Enrollment closed: PROPEL: Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD) (clinicaltrials.gov) - Feb 15, 2017
P=N/A, N=210, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed | Trial primary completion date: Aug 2018 --> Jan 2017 Recruiting --> Active, not recruiting
- Leukine (sargramostim) / Partner Therap, plerixafor / Generic mfg.
Trial completion: Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (clinicaltrials.gov) - Feb 11, 2017
P2, N=48, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Enrollment closed, Trial primary completion date: WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation (clinicaltrials.gov) - Feb 11, 2017
P=N/A, N=22, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Apr 2018
- | Trial completion, Surgery: Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma (clinicaltrials.gov) - Feb 6, 2017
P2, N=60, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Apr 2018 Active, not recruiting --> Completed
- || Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 3, 2017
P2, N=119, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Aug 2018
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment change, Trial termination, Trial primary completion date: NB2013-HR German (GPOH) / Dutch (DCOG) Trial (clinicaltrials.gov) - Feb 2, 2017
P2, N=3, Terminated, Sponsor: University of Cologne
Trial primary completion date: Aug 2017 --> Aug 2018 N=36 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Dec 2016; Antibody supply was discontinued by United Therapeutics Corporation.
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 30, 2017
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=36 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Dec 2016; Antibody supply was discontinued by United Therapeutics Corporation. Trial primary completion date: Jan 2017 --> Jan 2018
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) - Jan 26, 2017
P2, N=40, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Dec 2016 --> Nov 2017
- | UV1 / Ultimovacs
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (clinicaltrials.gov) - Jan 26, 2017
P1/2, N=12, Active, not recruiting, Sponsor: Ultimovacs AS
Trial primary completion date: Dec 2016 --> Nov 2017 Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Nov 2016 --> Nov 2019
- ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial primary completion date, Metastases: Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer (clinicaltrials.gov) - Jan 23, 2017
P2, N=53, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Nov 2016 --> Nov 2019 Trial primary completion date: Jan 2017 --> Oct 2017
- | Leukine (sargramostim) / Partner Therap
Trial completion: Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment (clinicaltrials.gov) - Jan 18, 2017
P2, N=0, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Jan 2017 --> Oct 2017 Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, FR Alpha Peptide Vaccine / National Cancer Institute
P2 data: Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 5, 2017
P2, N=280, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
- || Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Trial primary completion date: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) - Jan 4, 2017
P2, N=300, Recruiting, Sponsor: George E. Peoples
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date, IO biomarker: The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - Jan 4, 2017
P1, N=20, Recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Leukine (sargramostim) / Partner Therap
New P1 trial: Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis (clinicaltrials.gov) - Dec 30, 2016
P1, N=10, Not yet recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
- Leukine (sargramostim) / Partner Therap
Enrollment closed: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan (clinicaltrials.gov) - Dec 28, 2016
P2, N=80, Active, not recruiting, Sponsor: Niigata University Medical & Dental Hospital
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Trial completion: SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study (clinicaltrials.gov) - Dec 28, 2016
P1, N=14, Completed, Sponsor: Niigata University Medical & Dental Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial primary completion date: Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 21, 2016
P1, N=560, Recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed N=973 --> 560 | Trial primary completion date: Dec 2018 --> Jul 2019
- ||||||| Rintega (rindopepimut) / Celldex
Trial completion: Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Dec 15, 2016
P3, N=745, Completed, Sponsor: Celldex Therapeutics
N=973 --> 560 | Trial primary completion date: Dec 2018 --> Jul 2019 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's
Enrollment open, IO biomarker: VADIS: Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) - Dec 9, 2016
P2, N=108, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Recruiting
- Rituxan (rituximab) / Roche
Trial primary completion date: Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 7, 2016
P2, N=58, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Suspended --> Recruiting Trial primary completion date: Feb 2008 --> Jul 2003
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion, Trial primary completion date: Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Dec 2, 2016
P3, N=1449, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2008 --> Jul 2003 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2012
- || Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Trial primary completion date: Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (clinicaltrials.gov) - Nov 29, 2016
P2, N=100, Recruiting, Sponsor: Cancer Insight, LLC
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2012 Trial primary completion date: Oct 2016 --> Oct 2018
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (clinicaltrials.gov) - Nov 23, 2016
P2, N=30, Recruiting, Sponsor: Sanofi
Trial primary completion date: Oct 2016 --> Oct 2018 Trial primary completion date: Sep 2017 --> Apr 2018
- Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial primary completion date: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy (clinicaltrials.gov) - Nov 23, 2016
P1, N=18, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Sep 2017 --> Apr 2018 Trial primary completion date: Nov 2016 --> Nov 2017
- ||| Leukine (sargramostim) / Partner Therap
Trial initiation date, Trial primary completion date: Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia (clinicaltrials.gov) - Nov 23, 2016
P2, N=165, Not yet recruiting, Sponsor: Sanofi
Trial primary completion date: Nov 2016 --> Nov 2017 Initiation date: Jan 2017 --> Jul 2017 | Trial primary completion date: Jan 2022 --> Jul 2022
- |||| Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma (clinicaltrials.gov) - Nov 7, 2016
P2, N=52, Completed, Sponsor: M.D. Anderson Cancer Center
Initiation date: Jan 2017 --> Jul 2017 | Trial primary completion date: Jan 2022 --> Jul 2022 Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> Nov 2016
- UV1 / Ultimovacs
Trial primary completion date: A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (clinicaltrials.gov) - Nov 7, 2016
P1/2, N=18, Active, not recruiting, Sponsor: Ultimovacs AS
Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> Nov 2016 Trial primary completion date: Jul 2016 --> Feb 2020
- UV1 / Ultimovacs
Trial primary completion date, Metastases: A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer (clinicaltrials.gov) - Nov 7, 2016
P1/2, N=21, Active, not recruiting, Sponsor: Ultimovacs AS
Trial primary completion date: Jul 2016 --> Feb 2020 Trial primary completion date: Jul 2015 --> Jul 2020
- SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Enrollment closed, Trial primary completion date: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Nov 2, 2016
P1, N=9, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jul 2015 --> Jul 2020 Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2017
- | Leukine (sargramostim) / Partner Therap
Trial initiation date, Trial primary completion date: Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (clinicaltrials.gov) - Oct 26, 2016
P2, N=30, Recruiting, Sponsor: Sanofi
Completed --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2017 Initiation date: Jul 2016 --> Oct 2016 | Trial primary completion date: May 2018 --> Sep 2017
- Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial primary completion date: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Oct 18, 2016
P2, N=29, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Jul 2016 --> Oct 2016 | Trial primary completion date: May 2018 --> Sep 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (clinicaltrials.gov) - Oct 18, 2016
P1/2, N=30, Active, not recruiting, Sponsor: COL George Peoples, MD, FACS
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Oct 2016 --> Oct 2017